Redhill BiopharmaSTU:2RH 18 PB Ratio is 11.50 as of Jun. 25, 2026, which is 209% above its 10-year median of 3.72. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Redhill Biopharma ranks better than 73.32% on this metric.
The historical rank and industry rank for Redhill Biopharma's PB Ratio or its related term are showing as below:
STU:2RH'
s PB Ratio Range Over the Past 10 Years
Min: 0.82 Med: 3.72 Max: 29.9
Current: 1.06
During the past 13 years, Redhill Biopharma's highest PB Ratio was 29.90. The lowest was 0.82. And the median was 3.72.
STU:2RH's PB Ratio is ranked better than 73.32% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs STU:2RH: 1.06
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Redhill Biopharma was 22.90% per year. The lowest was -80.70% per year. And the median was -22.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Redhill Biopharma PB Ratio Related Terms
Redhill Biopharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Redhill Biopharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Redhill Biopharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Redhill Biopharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Redhill Biopharma (STU:2RH) has a PB Ratio of 11.50 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Redhill Biopharma and its competitors. This is 209% above median its historical median of 3.72. Over the past decade, Redhill Biopharma's PB Ratio has ranged from 0.82 to 29.90. According to the industry distribution chart, Redhill Biopharma ranks #246 out of 922 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is Redhill Biopharma's PB Ratio too high?
Redhill Biopharma's current PB Ratio of 11.50 is 209% above median its 10-year median of 3.72. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 29.90. The Drug Manufacturers industry median PB Ratio is 1.86. Redhill Biopharma's value of 11.50 is 519.9% above this industry median. Based on the distribution chart, Redhill Biopharma ranks #246 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's PB Ratio compare to LVRLF and BUDZ?
According to the Drug Manufacturers industry distribution chart, Redhill Biopharma ranks #246 out of 922 companies for PB Ratio. This puts Redhill Biopharma in the upper half of its industry. The industry median PB Ratio is 1.86. Redhill Biopharma's value of 11.50 is 519.9% above this benchmark. Historically, Redhill Biopharma's own PB Ratio has ranged from 0.82 to 29.90 over the past decade. While the company's 10-year median is 3.72 vs. the industry median of 1.86, Redhill Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Redhill Biopharma's current PB Ratio of 11.50 is 519.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Redhill Biopharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redhill Biopharma's current PB Ratio is 11.50, which is 209% above median its own 10-year median of 3.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current PB Ratio of 11.50. The current PB Ratio is 11.50, which is 209% above median its 10-year median of 3.72 and 519.9% above the Drug Manufacturers industry median of 1.86. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current PB Ratio is 11.50 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score
Get the complete analysis for STU:2RH
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RH has been successfully added to your 
